Six leading clinical trials07/11/2018 · News
The Institut de la Màcula has a variety of clinical trials with new drugs in progress. At present, three of them (the two devoted to DIABETIC MACULAR OEDEMA and the one to STARGARDT’S DISEASE) are in the process of recruiting individuals with this diagnosis who wish to participate voluntarily. Another three trials, one for GEOGRAPHIC ATROPHY, one for EXUDATIVE AMD and another also for DIABETIC MACULAR OEDEMA, will commence candidate selection soon
The patients who participate in these trials, free of charge, have the opportunity to be the first to be treated with new drugs that remain unavailable, while receiving specialised monitoring visits over a long period (between one or two years). Their participation is vital to discover new and improved treatments for these diseases.
Efficacy and security of brolucizumab compared to aflibercept in DIABETIC MACULAR OEDEMA
Aimed at patients of over 18 with Type 1 or 2 diabetes mellitus and visual disturbance due to diabetic macular oedema in the study eye that has not received prior treatment with any anti-VEGF drug. Visual acuity should be between 20/32 and 20/320. Duration: 24 months.
Efficacy and security of THR-317 with ranibizumab in DIABETIC MACULAR OEDEMA
Aimed at patients of over 18 who have been diagnosed with Type I or II diabetes, diagnosed in diabetic macular oedema and who have not been treated with anti-angiogenic agents or who have displayed an insufficient response to treatment with ranibizumab. Vision should be between 20/40 and 20/320. Duration: 5 months
Clinical Trial: RHINE - ROCHE
Phase III study to assess the simultaneous blocking of Angiopoietin-2 and VEGF-A with the antibody RO6867461 (RG7716) in DIABETIC MACULAR OEDEMA
Aimed at patients with diabetes I or II with diabetic macular oedema who have not received treatment with anti-VEGF in the three months prior to their visit. Duration: 24 months.
Efficacy and security of Zimura in the treatment of STARGARDT’S DISEASE
Aimed at patients of between 18 and 50 with a minimum of two pathogenic mutations in the ABCA4 gene that will be confirmed by the study laboratories. The visual acuity of patients should be between 20/20 and 20/200. Duration: 18 months.
Efficacy and security of APL-2 in GEOGRAPHIC ATROPHY
Aimed at patients of 60 or over with GA and without concomitant or prior wet AMD. Extra eligibility criteria are applied. Duration: 30 months.
If you are interested in taking part in a clinical trial, please send us your personal details here and we will assess whether you are eligible.Intravitreal injectionsStargardt diseaseDiabetic macular oedemaExudative or wet AMD